Clinical Trials
2 trialsNCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT00003880 2015-04-16
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 2/3 Terminated